HCT cohort demographics and clinical characteristics
| Characteristic . | N = 37 pairs (%) or median (IQR) . |
|---|---|
| Recipient age, y | 47 (39.5, 54) |
| Recipient sex | |
| Female | 14 (38) |
| Race/ethnicity (donor-recipient) | |
| White | 28 (76) |
| Asian/Pacific Islander | 5 (14) |
| Hispanic (mixed race) | 3 (8) |
| Black | 1 (3) |
| Donor age | 48.5 (36, 55) |
| Donor type | |
| Related | 36 (97) |
| Unrelated | 1 (3) |
| Donor sex | |
| Female | 22 (59) |
| HLA-matched | 36 (97) |
| HLA-mismatched (6/10 match) | 1 (3) |
| Underlying disease | |
| AML | 12 (32) |
| ALL | 2 (5) |
| CML | 12 (32) |
| CLL | 2 (5) |
| Myelodysplastic syndromes | 6 (16) |
| Non-Hodgkin lymphoma | 3 (8) |
| Disease severity | |
| Early disease | 23 (62) |
| Intermediate disease | 7 (19) |
| Advanced disease | 7 (19) |
| Cell source* | |
| Bone marrow | 11 (30) |
| Peripheral blood | 27 (73) |
| Treatment year | |
| 1999-2003 | 33 (89) |
| 2012-2013 | 4 (13) |
| CMV serostatus of pair | |
| D+/R+ | 21 (57) |
| D+/R− | 8 (22) |
| D−/R+ | 5 (14) |
| D−/R− | 3 (8) |
| Previous treatment regimens† | |
| Anti-CD20 | 3 (8) |
| Lymphodepletion | 13 (35) |
| Intensive chemotherapy (any) | 19 (51) |
| Conditioning regimen | |
| Bu/Cy, + ATG (1) or RAB (1) | 26 (70) |
| TBI, + Cy (5) or VP-16 (1) | 8 (22) |
| Bu, Flu | 3 (8) |
| GVHD prophylaxis | |
| CSA, MTX | 31 (84) |
| CSA, Cy | 4 (11) |
| CSA, MMF | 2 (5) |
| Systemic GVHD (by NIH criteria) | |
| Yes | 25 (68) |
| Characteristic . | N = 37 pairs (%) or median (IQR) . |
|---|---|
| Recipient age, y | 47 (39.5, 54) |
| Recipient sex | |
| Female | 14 (38) |
| Race/ethnicity (donor-recipient) | |
| White | 28 (76) |
| Asian/Pacific Islander | 5 (14) |
| Hispanic (mixed race) | 3 (8) |
| Black | 1 (3) |
| Donor age | 48.5 (36, 55) |
| Donor type | |
| Related | 36 (97) |
| Unrelated | 1 (3) |
| Donor sex | |
| Female | 22 (59) |
| HLA-matched | 36 (97) |
| HLA-mismatched (6/10 match) | 1 (3) |
| Underlying disease | |
| AML | 12 (32) |
| ALL | 2 (5) |
| CML | 12 (32) |
| CLL | 2 (5) |
| Myelodysplastic syndromes | 6 (16) |
| Non-Hodgkin lymphoma | 3 (8) |
| Disease severity | |
| Early disease | 23 (62) |
| Intermediate disease | 7 (19) |
| Advanced disease | 7 (19) |
| Cell source* | |
| Bone marrow | 11 (30) |
| Peripheral blood | 27 (73) |
| Treatment year | |
| 1999-2003 | 33 (89) |
| 2012-2013 | 4 (13) |
| CMV serostatus of pair | |
| D+/R+ | 21 (57) |
| D+/R− | 8 (22) |
| D−/R+ | 5 (14) |
| D−/R− | 3 (8) |
| Previous treatment regimens† | |
| Anti-CD20 | 3 (8) |
| Lymphodepletion | 13 (35) |
| Intensive chemotherapy (any) | 19 (51) |
| Conditioning regimen | |
| Bu/Cy, + ATG (1) or RAB (1) | 26 (70) |
| TBI, + Cy (5) or VP-16 (1) | 8 (22) |
| Bu, Flu | 3 (8) |
| GVHD prophylaxis | |
| CSA, MTX | 31 (84) |
| CSA, Cy | 4 (11) |
| CSA, MMF | 2 (5) |
| Systemic GVHD (by NIH criteria) | |
| Yes | 25 (68) |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATG, antithymocyte globulin; Bu, busulfan; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CSA, cyclosporine; Cy, cyclophosphamide; Flu, fludarabine; MMF, mycophenolate mofetil; MTX, methotrexate; NIH, National Institutes of Health; RAB, radiolabeled antibodies; TBI, total body irradiation; VP-16, etoposide.
Totals to 38; 1 person received both types of cells.
Anticancer or lymphodepleting agents given within the 12 mo prior to HCT were considered. The only anti-B-cell therapy given in this cohort was rituximab; no ofatumumab or anti-CD52 was given. Regimens considered to be lymphodepleting included rituximab, fludarabine, high-dose cytarabine, or cycloporin/ifosphamide, or combinations of the preceding.